Artiva Biotherapeutics, Inc.

Contributing Author

Recent Articles by Artiva Biotherapeutics, Inc.

Mar-10	Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights ARTV +17.27% ARTV +6.48% GlobeNewswire
Feb-25	Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference ARTV GlobeNewswire
Feb-24	Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant ARTV GlobeNewswire
Feb-19	Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors ARTV +9.16% GlobeNewswire
Jan-21	Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL ARTV GlobeNewswire
Nov-12	Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK in Autoimmune Disease ARTV +10.86% GlobeNewswire
Nov-12	Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights ARTV +10.86% GlobeNewswire
Nov-03	Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK ARTV -9.59% GlobeNewswire
Oct-30	Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November ARTV -10.25% ARTV +5.84% GlobeNewswire
Oct-16	Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update ARTV +116.97% ARTV -7.97% GlobeNewswire
Aug-25	Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025 ARTV GlobeNewswire
Aug-06	Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights ARTV -8.01% ARTV -6.82% GlobeNewswire
May-28	Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference ARTV +6.77% ARTV GlobeNewswire
May-13	Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting ARTV -11.71% ARTV GlobeNewswire
May-08	Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights ARTV GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)